{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T23:06:56Z","timestamp":1779318416787,"version":"3.51.4"},"reference-count":127,"publisher":"Springer Science and Business Media LLC","issue":"S4","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010109","name":"Medical University of Graz","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100010109","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>Epidemiologische Untersuchungen zeigen, dass etwa 2\u20133\u202f% aller \u00d6sterreicher*innen einen Diabetes mellitus mit Nierenbeteiligung aufweisen. Dies betrifft somit in \u00d6sterreich etwa 250.000 Menschen. Das Risiko des Auftretens und Fortschreitens der diabetischen Nierenerkrankung (DKD) kann durch Lebensstilinterventionen und Optimierung des arteriellen Blutdrucks, Blutzuckers und durch spezifische Medikamentenklassen vermindert werden. In dieser gemeinsamen Leitlinie der \u00d6sterreichischen Gesellschaften f\u00fcr Nephrologie und Diabetologie werden die Definition, entsprechende Diagnostik und therapeutische Strategien bei DKD vorgeschlagen.<\/jats:p>","DOI":"10.1007\/s00508-025-02671-y","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T22:18:38Z","timestamp":1779315518000},"page":"213-227","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Diabetische Nierenerkrankung (Update 2026)","Diabetic kidney disease (Update 2026)"],"prefix":"10.1007","volume":"138","author":[{"given":"Harald","family":"Sourij","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Aberer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marlies","family":"Antlanger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna","family":"Brix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Cejka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Clodi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland","family":"Edlinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathrin","family":"Eller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Horn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne","family":"Kaser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Kautzky-Willer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Leutner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rainer","family":"Oberbauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Pirklbauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander R.","family":"Rosenkranz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Schmaldienst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harald","family":"Stingl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Strobl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus","family":"S\u00e4emann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"key":"2671_CR1","volume-title":"\u00d6sterreichisches Dialyse- und Transplantationsregister","author":"\u00d6sterreichische Gesellschaft f\u00fcr Nephrologie.","year":"2022","unstructured":"\u00d6sterreichische Gesellschaft f\u00fcr Nephrologie.. \u00d6sterreichisches Dialyse- und Transplantationsregister. 2022."},{"key":"2671_CR2","volume-title":"Austrian Dialysis and Transplant Registry","author":"R Kramar","year":"2016","unstructured":"Kramar\u00a0R. Austrian Dialysis and Transplant Registry. 2016."},{"key":"2671_CR3","unstructured":"Jahresbericht des \u00f6sterreichischen Dialyse- und Transplantationsregisters (2023)."},{"key":"2671_CR4","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1093\/ndt\/gfv113","volume":"30","author":"FC Prischl","year":"2015","unstructured":"Prischl\u00a0FC, et\u00a0al. Diabetes-related end-stage renal disease in Austria 1965\u20132013. Nephrol Dial Transplant. 2015;30:1920\u20137.","journal-title":"Nephrol Dial Transplant"},{"key":"2671_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2337\/dc13-2112","volume":"37","author":"DM Nathan","year":"2014","unstructured":"Nathan\u00a0DM. The diabetes control and complications trial\/epidemiology of diabetes interventions and complications study at 30\u00a0years: overview. Diabetes Care. 2014;37:9\u201316. Group, D.E.R..","journal-title":"Diabetes Care"},{"key":"2671_CR6","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1681\/ASN.2013091004","volume":"25","author":"IH de Boer","year":"2014","unstructured":"de Boer\u00a0IH, et\u00a0al. Renal outcomes in patients with type\u00a01 diabetes and macroalbuminuria. J\u00a0Am Soc Nephrol. 2014;25:2342\u201350.","journal-title":"J Am Soc Nephrol"},{"key":"2671_CR7","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.kint.2022.08.012","volume":"102","author":"IH de Boer","year":"2022","unstructured":"de Boer\u00a0IH, et\u00a0al. Diabetes management in chronic kidney disease: a\u00a0consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2022;102:974\u201389.","journal-title":"Kidney Int"},{"key":"2671_CR8","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.2337\/dci22-0027","volume":"45","author":"IH de Boer","year":"2022","unstructured":"de Boer\u00a0IH, et\u00a0al. Diabetes management in chronic kidney disease: a\u00a0consensus report by the American diabetes association (ADA) and kidney disease: improving global outcomes (KDIGO). Diabetes Care. 2022;45:3075\u201390.","journal-title":"Diabetes Care"},{"key":"2671_CR9","doi-asserted-by":"crossref","unstructured":"Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 355, 253\u2013259 (2000).","DOI":"10.1016\/S0140-6736(99)12323-7"},{"key":"2671_CR10","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner\u00a0BM, et\u00a0al. Effects of losartan on renal and cardiovascular outcomes in patients with type\u00a02 diabetes and nephropathy. N\u00a0Engl J Med. 2001;345:861\u20139.","journal-title":"N Engl J Med"},{"key":"2671_CR11","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"EJ Lewis","year":"2001","unstructured":"Lewis\u00a0EJ, et\u00a0al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type\u00a02 diabetes. N\u00a0Engl J Med. 2001;345:851\u201360.","journal-title":"N Engl J Med"},{"key":"2671_CR12","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1056\/NEJMoa011489","volume":"345","author":"HH Parving","year":"2001","unstructured":"Parving\u00a0HH, et\u00a0al. The effect of irbesartan on the development of diabetic nephropathy in patients with type\u00a02 diabetes. N\u00a0Engl J Med. 2001;345:870\u20138.","journal-title":"N Engl J Med"},{"key":"2671_CR13","doi-asserted-by":"crossref","unstructured":"Sourij C, et\u00a0al. Prevalence of undiagnosed diabetes and prediabetes according to age and obesity status in Central Europe. Obes Facts. 2025; 1\u201316.","DOI":"10.1159\/000547108"},{"key":"2671_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/rssa.12682","author":"A Geroldinger","year":"2019","unstructured":"Geroldinger\u00a0A, Hronsky\u00a0HA, Endel\u00a0F, Endel\u00a0G, Oberbauer\u00a0R, Heinze\u00a0G. Estimation of the prevalence of chronic kidney disease in people with diabetes by combining information from multiple routine data collections. J\u00a0R Stat Socc Ser\u00a0A. 2019; https:\/\/doi.org\/10.1111\/rssa.12682.","journal-title":"J R Stat Socc Ser A"},{"key":"2671_CR15","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1046\/j.1523-1755.2003.00712.x","volume":"63","author":"AI Adler","year":"2003","unstructured":"Adler\u00a0AI, et\u00a0al. Development and progression of nephropathy in type\u00a02 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS\u00a064). Kidney Int. 2003;63:225\u201332.","journal-title":"Kidney Int"},{"key":"2671_CR16","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1016\/S0140-6736(12)61350-6","volume":"380","author":"CS Fox","year":"2012","unstructured":"Fox\u00a0CS, et\u00a0al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a\u00a0meta-analysis. Lancet. 2012;380:1662\u201373.","journal-title":"Lancet"},{"key":"2671_CR17","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1093\/ajcp\/38.3.270","volume":"38","author":"P Kimmelstiel","year":"1962","unstructured":"Kimmelstiel\u00a0P, Kim\u00a0OJ, Beres\u00a0J. Studies on renal biopsy specimens, with the aid of the electron microscope. I. Glomeruli in diabetes. Am J Clin Pathol. 1962;38:270\u20139.","journal-title":"Am J Clin Pathol"},{"key":"2671_CR18","first-page":"83","volume":"12","author":"P Kimmelstiel","year":"1936","unstructured":"Kimmelstiel\u00a0P, Wilson\u00a0C. Intercapillary Lesions in the Glomeruli of the Kidney. Am J Pathol. 1936;12:83\u201398.","journal-title":"Am J Pathol"},{"issue":"Suppl 2","key":"2671_CR19","doi-asserted-by":"publisher","first-page":"64","DOI":"10.2337\/diab.32.2.S64","volume":"32","author":"CE Mogensen","year":"1983","unstructured":"Mogensen\u00a0CE, Christensen\u00a0CK, Vittinghus\u00a0E. The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. Diabetes. 1983;32(Suppl 2):64\u201378.","journal-title":"Diabetes"},{"key":"2671_CR20","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1172\/JCI111523","volume":"74","author":"SM Mauer","year":"1984","unstructured":"Mauer\u00a0SM, et\u00a0al. Structural-functional relationships in diabetic nephropathy. J\u00a0Clin Invest. 1984;74:1143\u201355.","journal-title":"J Clin Invest"},{"issue":"Suppl 4","key":"2671_CR21","first-page":"958","volume":"5","author":"JM Steinke","year":"2008","unstructured":"Steinke\u00a0JM, Mauer\u00a0M, Diabetic Nephropathy Study\u00a0IG. Lessons learned from studies of the natural history of diabetic nephropathy in young type\u00a01 diabetic patients. Pediatr Endocrinol Rev. 2008;5(Suppl 4):958\u201363.","journal-title":"Pediatr Endocrinol Rev"},{"issue":"Suppl 2","key":"2671_CR22","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s00508-012-0262-6","volume":"124","author":"M Auinger","year":"2012","unstructured":"Auinger\u00a0M, et\u00a0al. Diabetic nephropathy\u2014update 2012. Wien Klin Wochenschr. 2012;124(Suppl 2):42\u20139.","journal-title":"Wien Klin Wochenschr"},{"key":"2671_CR23","doi-asserted-by":"publisher","first-page":"3273","DOI":"10.1001\/jama.289.24.3273","volume":"289","author":"HJ Kramer","year":"2003","unstructured":"Kramer\u00a0HJ, Nguyen\u00a0QD, Curhan\u00a0G, Hsu\u00a0CY. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type\u00a02 diabetes mellitus. JAMA. 2003;289:3273\u20137.","journal-title":"JAMA"},{"key":"2671_CR24","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.2337\/db05-1620","volume":"55","author":"R Retnakaran","year":"2006","unstructured":"Retnakaran\u00a0R, et\u00a0al. Risk factors for renal dysfunction in type\u00a02 diabetes: U.K. Prospective Diabetes Study\u00a074. Diabetes. 2006;55:1832\u20139.","journal-title":"Diabetes"},{"key":"2671_CR25","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1471-2369-14-46","volume":"14","author":"A Rodriguez-Poncelas","year":"2013","unstructured":"Rodriguez-Poncelas\u00a0A, et\u00a0al. Prevalence of chronic kidney disease in patients with type\u00a02 diabetes in Spain: PERCEDIME2 study. BMC Nephrol. 2013;14:46.","journal-title":"BMC Nephrol"},{"key":"2671_CR26","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.2337\/dc08-2186","volume":"32","author":"MC Thomas","year":"2009","unstructured":"Thomas\u00a0MC, et\u00a0al. Nonalbuminuric renal impairment in type\u00a02 diabetic patients and in the general population (national evaluation of the frequency of renal impairment cO-existing with NIDDM [NEFRON] 11). Diabetes Care. 2009;32:1497\u2013502.","journal-title":"Diabetes Care"},{"key":"2671_CR27","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/S0140-6736(10)60576-4","volume":"376","author":"F Ismail-Beigi","year":"2010","unstructured":"Ismail-Beigi\u00a0F, et\u00a0al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type\u00a02 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010;376:419\u201330.","journal-title":"Lancet"},{"key":"2671_CR28","doi-asserted-by":"publisher","first-page":"954","DOI":"10.2337\/dc15-0184","volume":"38","author":"AS Krolewski","year":"2015","unstructured":"Krolewski\u00a0AS. Progressive renal decline: the new paradigm of diabetic nephropathy in type\u00a01 diabetes. Diabetes Care. 2015;38:954\u201362.","journal-title":"Diabetes Care"},{"key":"2671_CR29","doi-asserted-by":"publisher","first-page":"436","DOI":"10.2337\/dc21-1688","volume":"45","author":"HC Looker","year":"2022","unstructured":"Looker\u00a0HC, et\u00a0al. Structural Lesions on Kidney Biopsy in Youth-Onset and Adult-Onset Type\u00a02 Diabetes. Diabetes Care. 2022;45:436\u201343.","journal-title":"Diabetes Care"},{"key":"2671_CR30","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1681\/ASN.2010010010","volume":"21","author":"TW Tervaert","year":"2010","unstructured":"Tervaert\u00a0TW, et\u00a0al. Pathologic classification of diabetic nephropathy. J\u00a0Am Soc Nephrol. 2010;21:556\u201363.","journal-title":"J Am Soc Nephrol"},{"key":"2671_CR31","doi-asserted-by":"crossref","unstructured":"de Boer IH, et\u00a0al. Diabetes Management in Chronic Kidney Disease: A\u00a0Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care. 2022;.","DOI":"10.2337\/figshare.20272404"},{"key":"2671_CR32","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1373\/clinchem.2006.077180","volume":"53","author":"AS Levey","year":"2007","unstructured":"Levey\u00a0AS, et\u00a0al. Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem. 2007;53:766\u201372.","journal-title":"Clin Chem"},{"key":"2671_CR33","doi-asserted-by":"crossref","unstructured":"Fu EL, et\u00a0al. Removing race from the CKD-EPI equation and its impact on prognosis in a\u00a0predominantly White European population. Nephrol Dial Transplant. 2022;.","DOI":"10.1093\/ndt\/gfac197"},{"key":"2671_CR34","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey\u00a0AS, et\u00a0al. A\u00a0new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604\u201312.","journal-title":"Ann Intern Med"},{"key":"2671_CR35","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1001\/jama.2012.4623","volume":"307","author":"K Kalantar-Zadeh","year":"2012","unstructured":"Kalantar-Zadeh\u00a0K, Amin\u00a0AN. Toward more accurate detection and risk stratification of chronic kidney disease. JAMA. 2012;307:1976\u20137.","journal-title":"JAMA"},{"key":"2671_CR36","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1053\/j.ajkd.2009.12.011","volume":"55","author":"SL White","year":"2010","unstructured":"White\u00a0SL, Polkinghorne\u00a0KR, Atkins\u00a0RC, Chadban\u00a0SJ. Comparison of the prevalence and mortality risk of CKD in Australia using the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) Study GFR estimating equations: the AusDiab (Australian Diabetes, Obesity and Lifestyle) Study. Am J Kidney Dis. 2010;55:660\u201370.","journal-title":"Am J Kidney Dis"},{"key":"2671_CR37","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","volume":"130","author":"AS Levey","year":"1999","unstructured":"Levey\u00a0AS, et\u00a0al. A\u00a0more accurate method to estimate glomerular filtration rate from serum creatinine: a\u00a0new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461\u201370.","journal-title":"Ann Intern Med"},{"key":"2671_CR38","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"KDIGO","year":"2024","unstructured":"KDIGO. 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105:S117\u2013S314.","journal-title":"Kidney Int"},{"key":"2671_CR39","doi-asserted-by":"publisher","first-page":"g4507","DOI":"10.1136\/bmj.g4507","volume":"349","author":"S Carville","year":"2014","unstructured":"Carville\u00a0S, Wonderling\u00a0D, Stevens\u00a0P. Early identification and management of chronic kidney disease in adults: summary of updated NICE guidance. BMJ. 2014;349:g4507. Guideline Development, G..","journal-title":"BMJ"},{"key":"2671_CR40","doi-asserted-by":"publisher","first-page":"S105","DOI":"10.2337\/dc18-S010","volume":"41","author":"A American Diabetes","year":"2018","unstructured":"American Diabetes\u00a0A. 10. Microvascular complications and foot care: standards of medical care in diabetes\u20142018. Diabetes Care. 2018;41:S105\u2013S18.","journal-title":"Diabetes Care"},{"key":"2671_CR41","doi-asserted-by":"publisher","first-page":"239","DOI":"10.2337\/dc25-S011","volume":"48","author":"American Diabetes Association Professional Practice, C","year":"2025","unstructured":"American Diabetes Association Professional Practice, C. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes\u20142025. Diabetes Care. 2025;48:239\u2013S51.","journal-title":"Diabetes Care"},{"key":"2671_CR42","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1053\/j.ajkd.2023.12.018","volume":"84","author":"N Rasaratnam","year":"2024","unstructured":"Rasaratnam\u00a0N, et\u00a0al. Urine albumin-Creatinine ratio variability in people with type\u00a02 diabetes: clinical and research implications. Am J Kidney Dis. 2024;84:8\u201317e11.","journal-title":"Am J Kidney Dis"},{"key":"2671_CR43","doi-asserted-by":"publisher","first-page":"4602","DOI":"10.1111\/dom.15817","volume":"26","author":"A Oulhaj","year":"2024","unstructured":"Oulhaj\u00a0A, et\u00a0al. Estimated glomerular filtration rate slope and risk of primary and secondary major adverse cardiovascular events and heart failure hospitalization in people with type\u00a02 diabetes: An analysis of the EXSCEL trial. Diabetes Obes Metab. 2024;26:4602\u201312.","journal-title":"Diabetes Obes Metab"},{"key":"2671_CR44","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2020.06.019","volume":"98","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group","year":"2020","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2020;98:S1\u2013S115.","journal-title":"Kidney Int"},{"key":"2671_CR45","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","volume":"102","author":"Kidney Disease: Improving Global Outcomes Diabetes Work, G.","year":"2022","unstructured":"Kidney Disease: Improving Global Outcomes Diabetes Work, G.. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022;102:S1\u2013S127.","journal-title":"Kidney Int"},{"key":"2671_CR46","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1093\/ajcn\/nqab417","volume":"115","author":"V Bellizzi","year":"2022","unstructured":"Bellizzi\u00a0V, et\u00a0al. No additional benefit of prescribing a\u00a0very low-protein diet in patients with advanced chronic kidney disease under regular nephrology care: a\u00a0pragmatic, randomized, controlled trial. Am J Clin Nutr. 2022;115:1404\u201317.","journal-title":"Am J Clin Nutr"},{"key":"2671_CR47","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1007\/s13668-021-00383-z","volume":"11","author":"FP Cappuccio","year":"2022","unstructured":"Cappuccio\u00a0FP, et\u00a0al. Sodium and health: Old myths and a\u00a0controversy based on denial. Curr Nutr Rep. 2022;11:172\u201384.","journal-title":"Curr Nutr Rep"},{"key":"2671_CR48","doi-asserted-by":"publisher","first-page":"703","DOI":"10.2337\/dc10-1723","volume":"34","author":"EI Ekinci","year":"2011","unstructured":"Ekinci\u00a0EI, et\u00a0al. Dietary salt intake and mortality in patients with type\u00a02 diabetes. Diabetes Care. 2011;34:703\u20139.","journal-title":"Diabetes Care"},{"key":"2671_CR49","doi-asserted-by":"publisher","first-page":"861","DOI":"10.2337\/dc10-1722","volume":"34","author":"MC Thomas","year":"2011","unstructured":"Thomas\u00a0MC, et\u00a0al. The association between dietary sodium intake, ESRD, and all-cause mortality in patients with type\u00a01 diabetes. Diabetes Care. 2011;34:861\u20136.","journal-title":"Diabetes Care"},{"key":"2671_CR50","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/j.kint.2018.12.027","volume":"95","author":"T Banerjee","year":"2019","unstructured":"Banerjee\u00a0T, et\u00a0al. Poor accordance to a\u00a0DASH dietary pattern is associated with higher risk of ESRD among adults with moderate chronic kidney disease and hypertension. Kidney Int. 2019;95:1433\u201342.","journal-title":"Kidney Int"},{"key":"2671_CR51","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1016\/j.clnu.2019.10.004","volume":"39","author":"H Mozaffari","year":"2020","unstructured":"Mozaffari\u00a0H, Ajabshir\u00a0S, Alizadeh\u00a0S. Dietary approaches to stop hypertension and risk of chronic kidney disease: a\u00a0systematic review and meta-analysis of observational studies. Clin Nutr. 2020;39:2035\u201344.","journal-title":"Clin Nutr"},{"key":"2671_CR52","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1093\/ckj\/sfw046","volume":"9","author":"CC Tyson","year":"2016","unstructured":"Tyson\u00a0CC, et\u00a0al. Short-term effects of the DASH diet in adults with moderate chronic kidney disease: a\u00a0pilot feeding study. Clin Kidney\u00a0J. 2016;9:592\u20138.","journal-title":"Clin Kidney J"},{"key":"2671_CR53","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1093\/ndt\/gfx352","volume":"33","author":"E Yuzbashian","year":"2018","unstructured":"Yuzbashian\u00a0E, Asghari\u00a0G, Mirmiran\u00a0P, Amouzegar-Bahambari\u00a0P, Azizi\u00a0F. Adherence to low-sodium Dietary Approaches to Stop Hypertension-style diet may decrease the risk of incident chronic kidney disease among high-risk patients: a\u00a0secondary prevention in prospective cohort study. Nephrol Dial Transplant. 2018;33:1159\u201368.","journal-title":"Nephrol Dial Transplant"},{"key":"2671_CR54","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/s41581-020-0323-4","volume":"16","author":"NG Docherty","year":"2020","unstructured":"Docherty\u00a0NG, le Roux\u00a0CW. Bariatric surgery for the treatment of chronic kidney disease in obesity and type\u00a02 diabetes mellitus. Nat Rev Nephrol. 2020;16:709\u201320.","journal-title":"Nat Rev Nephrol"},{"key":"2671_CR55","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2337\/dc18-S007","volume":"41","author":"American Diabetes, A.","year":"2018","unstructured":"American Diabetes, A.. 7. Obesity management for the treatment of type\u00a02 diabetes: standards of medical care in diabetes\u20142018. Diabetes Care. 2018;41:65\u2013S72.","journal-title":"Diabetes Care"},{"key":"2671_CR56","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/S0140-6736(13)60595-4","volume":"382","author":"RT Gansevoort","year":"2013","unstructured":"Gansevoort\u00a0RT, et\u00a0al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;382:339\u201352.","journal-title":"Lancet"},{"key":"2671_CR57","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/S0140-6736(12)60572-8","volume":"380","author":"M Tonelli","year":"2012","unstructured":"Tonelli\u00a0M, et\u00a0al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a\u00a0population-level cohort study. Lancet. 2012;380:807\u201314.","journal-title":"Lancet"},{"key":"2671_CR58","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1053\/j.ajkd.2014.08.001","volume":"64","author":"KR Tuttle","year":"2014","unstructured":"Tuttle\u00a0KR, et\u00a0al. Diabetic kidney disease: a\u00a0report from an ADA Consensus Conference. Am J Kidney Dis. 2014;64:510\u201333.","journal-title":"Am J Kidney Dis"},{"key":"2671_CR59","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41581-018-0072-9","volume":"14","author":"CJ Ferro","year":"2018","unstructured":"Ferro\u00a0CJ, et\u00a0al. Lipid management in patients with chronic kidney disease. Nat Rev Nephrol. 2018;14:727\u201349.","journal-title":"Nat Rev Nephrol"},{"key":"2671_CR60","doi-asserted-by":"publisher","first-page":"263","DOI":"10.7326\/0003-4819-157-4-201208210-00007","volume":"157","author":"SC Palmer","year":"2012","unstructured":"Palmer\u00a0SC, et\u00a0al. Benefits and harms of statin therapy for persons with chronic kidney disease: a\u00a0systematic review and meta-analysis. Ann Intern Med. 2012;157:263\u201375.","journal-title":"Ann Intern Med"},{"key":"2671_CR61","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1053\/j.ajkd.2016.01.016","volume":"67","author":"X Su","year":"2016","unstructured":"Su\u00a0X, et\u00a0al. Effect of statins on kidney disease outcomes: a\u00a0systematic review and meta-analysis. Am J Kidney Dis. 2016;67:881\u201392.","journal-title":"Am J Kidney Dis"},{"key":"2671_CR62","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","volume":"377","author":"C Baigent","year":"2011","unstructured":"Baigent\u00a0C, et\u00a0al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a\u00a0randomised placebo-controlled trial. Lancet. 2011;377:2181\u201392.","journal-title":"Lancet"},{"key":"2671_CR63","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1681\/ASN.2013090965","volume":"25","author":"R Haynes","year":"2014","unstructured":"Haynes\u00a0R, et\u00a0al. Effects of lowering LDL cholesterol on progression of kidney disease. J\u00a0Am Soc Nephrol. 2014;25:1825\u201333.","journal-title":"J Am Soc Nephrol"},{"key":"2671_CR64","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd007784.pub3","author":"DJ Tunnicliffe","year":"2023","unstructured":"Tunnicliffe\u00a0DJ, et\u00a0al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev. 2023; https:\/\/doi.org\/10.1002\/14651858.cd007784.pub3.","journal-title":"Cochrane Database Syst Rev"},{"key":"2671_CR65","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s11883-025-01290-2","volume":"27","author":"P Theofilis","year":"2025","unstructured":"Theofilis\u00a0P, Vlachakis\u00a0PK, Karakasis\u00a0P, Kalaitzidis\u00a0RG. Managing dyslipidemia in chronic kidney disease: implications for cardiovascular and renal risk. Curr Atheroscler Rep. 2025;27:41.","journal-title":"Curr Atheroscler Rep"},{"key":"2671_CR66","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1016\/j.jacc.2019.03.513","volume":"73","author":"DM Charytan","year":"2019","unstructured":"Charytan\u00a0DM, et\u00a0al. Efficacy and safety of evolocumab in chronic kidney disease in the FOURIER trial. J\u00a0Am Coll Cardiol. 2019;73:2961\u201370.","journal-title":"J Am Coll Cardiol"},{"key":"2671_CR67","doi-asserted-by":"publisher","first-page":"4114","DOI":"10.1093\/eurheartj\/ehaa498","volume":"41","author":"J Tunon","year":"2020","unstructured":"Tunon\u00a0J, et\u00a0al. Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a\u00a0recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial. Eur Heart\u00a0J. 2020;41:4114\u201323.","journal-title":"Eur Heart J"},{"issue":"6","key":"2671_CR68","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.kint.2017.12.011","volume":"93","author":"PP Toth","year":"2018","unstructured":"Toth\u00a0PP, et\u00a0al. Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease. Kidney Int. 2018;93(6):1397\u2013408. https:\/\/doi.org\/10.1016\/j.kint.2017.12.011.","journal-title":"Kidney Int"},{"key":"2671_CR69","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.mayocp.2019.08.021","volume":"95","author":"RS Wright","year":"2020","unstructured":"Wright\u00a0RS, et\u00a0al. Effects of renal impairment on the pharmacokinetics, efficacy, and safety of Inclisiran: an analysis of the ORION\u20117 and ORION\u20111 studies. Mayo Clin Proc. 2020;95:77\u201389.","journal-title":"Mayo Clin Proc"},{"key":"2671_CR70","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","volume":"388","author":"SE Nissen","year":"2023","unstructured":"Nissen\u00a0SE, et\u00a0al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N\u00a0Engl J Med. 2023;388:1353\u201364.","journal-title":"N Engl J Med"},{"key":"2671_CR71","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/S2213-8587(24)00063-9","volume":"12","author":"KK Ray","year":"2024","unstructured":"Ray\u00a0KK, Bloedon\u00a0L, Li\u00a0N, Nissen\u00a0SE. Evaluating the effect of bempedoic acid on kidney function: call for cautious implementation\u2014Authors\u2019 reply. Lancet Diabetes Endocrinol. 2024;12:228\u20139.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2671_CR72","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","volume":"360","author":"BC Fellstrom","year":"2009","unstructured":"Fellstrom\u00a0BC, et\u00a0al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N\u00a0Engl J Med. 2009;360:1395\u2013407.","journal-title":"N Engl J Med"},{"key":"2671_CR73","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1056\/NEJMoa043545","volume":"353","author":"C Wanner","year":"2005","unstructured":"Wanner\u00a0C, et\u00a0al. Atorvastatin in patients with type\u00a02 diabetes mellitus undergoing hemodialysis. N\u00a0Engl J Med. 2005;353:238\u201348.","journal-title":"N Engl J Med"},{"key":"2671_CR74","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1097\/TP.0b013e3182861945","volume":"95","author":"C Margreiter","year":"2013","unstructured":"Margreiter\u00a0C, et\u00a0al. Combined pancreas-kidney transplantation for patients with end-stage nephropathy caused by type\u20112 diabetes mellitus. Transplantation. 2013;95:1030\u20136.","journal-title":"Transplantation"},{"key":"2671_CR75","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1056\/NEJMoa1407963","volume":"371","author":"S Zoungas","year":"2014","unstructured":"Zoungas\u00a0S, et\u00a0al. Follow-up of blood-pressure lowering and glucose control in type\u00a02 diabetes. N\u00a0Engl J Med. 2014;371:1392\u2013406.","journal-title":"N Engl J Med"},{"key":"2671_CR76","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/j.ekir.2018.04.008","volume":"3","author":"FC Prischl","year":"2018","unstructured":"Prischl\u00a0FC, Wanner\u00a0C. Renal outcomes of antidiabetic treatment options for type\u00a02 diabetes\u2014A proposed MARE definition. Kidney Int Rep. 2018;3:1030\u20138.","journal-title":"Kidney Int Rep"},{"key":"2671_CR77","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1056\/NEJMoa1515920","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner\u00a0C, Inzucchi\u00a0SE, Zinman\u00a0B. Empagliflozin and progression of kidney disease in type\u00a02 diabetes. N\u00a0Engl J Med. 2016;375:1801\u20132.","journal-title":"N Engl J Med"},{"key":"2671_CR78","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal\u00a0B, et\u00a0al. Canagliflozin and cardiovascular and renal events in type\u00a02 diabetes. N\u00a0Engl J Med. 2017;377:644\u201357.","journal-title":"N Engl J Med"},{"key":"2671_CR79","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott\u00a0SD, et\u00a0al. Dapagliflozin and cardiovascular outcomes in type\u00a02 diabetes. N\u00a0Engl J Med. 2019;380:347\u201357.","journal-title":"N Engl J Med"},{"key":"2671_CR80","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink\u00a0HJL, et\u00a0al. Dapagliflozin in patients with chronic kidney disease. N\u00a0Engl J Med. 2020;383:1436\u201346.","journal-title":"N Engl J Med"},{"key":"2671_CR81","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic\u00a0V, et\u00a0al. Canagliflozin and renal outcomes in type\u00a02 diabetes and nephropathy. N\u00a0Engl J Med. 2019;380:2295\u2013306.","journal-title":"N Engl J Med"},{"key":"2671_CR82","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2204233","author":"EMPA-KIDNEY Collaborative Group","year":"2022","unstructured":"EMPA-KIDNEY Collaborative Group, et\u00a0al. Empagliflozin in patients with chronic kidney disease. N\u00a0Engl J Med. 2022; https:\/\/doi.org\/10.1056\/nejmoa2204233.","journal-title":"N Engl J Med"},{"key":"2671_CR83","doi-asserted-by":"crossref","unstructured":"Kidney Disease: Improving Global Outcomes, C.K.D.W.G. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int 105, S117\u2013S314 (2024).","DOI":"10.1016\/j.kint.2023.10.018"},{"key":"2671_CR84","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/dom.14248","volume":"23","author":"M Phillip","year":"2021","unstructured":"Phillip\u00a0M, et\u00a0al. Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type\u00a01 diabetes: pooled 52-week outcomes from the DEPICT\u20111 and -2\u00a0studies. Diabetes Obes Metab. 2021;23:549\u201360.","journal-title":"Diabetes Obes Metab"},{"key":"2671_CR85","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.2337\/dc18-1749","volume":"41","author":"J Rosenstock","year":"2018","unstructured":"Rosenstock\u00a0J, et\u00a0al. Empagliflozin as adjunctive to insulin therapy in type\u00a01 diabetes: the EASE trials. Diabetes Care. 2018;41:2560\u20139.","journal-title":"Diabetes Care"},{"key":"2671_CR86","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14061180","author":"F Aberer","year":"2022","unstructured":"Aberer\u00a0F, Pieber\u00a0TR, Eckstein\u00a0ML, Sourij\u00a0H, Moser\u00a0O. Glucose-lowering therapy beyond insulin in type\u00a01 diabetes: a\u00a0narrative review on existing evidence from randomized controlled trials and clinical perspective. Pharmaceutics. 2022; https:\/\/doi.org\/10.3390\/pharmaceutics14061180.","journal-title":"Pharmaceutics"},{"key":"2671_CR87","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S2213-8587(20)30280-1","volume":"8","author":"PH Groop","year":"2020","unstructured":"Groop\u00a0PH, et\u00a0al. Effect of dapagliflozin as an adjunct to insulin over 52\u00a0weeks in individuals with type\u00a01 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials. Lancet Diabetes Endocrinol. 2020;8:845\u201354.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2671_CR88","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.2215\/CJN.07700621","volume":"16","author":"DZI Cherney","year":"2021","unstructured":"Cherney\u00a0DZI, et\u00a0al. Kidney effects of Empagliflozin in people with type\u00a01 diabetes. Clin J Am Soc Nephrol. 2021;16:1715\u20139.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2671_CR89","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03723-6","author":"FH Mahmud","year":"2025","unstructured":"Mahmud\u00a0FH, et\u00a0al. Adjunct-to-insulin therapy using SGLT2 inhibitors in youth with type\u00a01 diabetes: a\u00a0randomized controlled trial. Nat Med. 2025; https:\/\/doi.org\/10.1038\/s41591-025-03723-6.","journal-title":"Nat Med"},{"key":"2671_CR90","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic\u00a0V, et\u00a0al. Effects of semaglutide on chronic kidney disease in patients with type\u00a02 diabetes. N\u00a0Engl J Med. 2024;391:109\u201321.","journal-title":"N Engl J Med"},{"key":"2671_CR91","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso\u00a0SP, et\u00a0al. Liraglutide and cardiovascular outcomes in type\u00a02 diabetes. N\u00a0Engl J Med. 2016;375:311\u201322.","journal-title":"N Engl J Med"},{"key":"2671_CR92","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein\u00a0HC, et\u00a0al. Dulaglutide and cardiovascular outcomes in type\u00a02 diabetes (REWIND): a\u00a0double-blind, randomised placebo-controlled trial. Lancet. 2019;394:121\u201330.","journal-title":"Lancet"},{"key":"2671_CR93","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0140-6736(19)31150-X","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein\u00a0HC, et\u00a0al. Dulaglutide and renal outcomes in type\u00a02 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet. 2019;394:131\u20138.","journal-title":"Lancet"},{"key":"2671_CR94","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso\u00a0SP, et\u00a0al. Semaglutide and cardiovascular outcomes in patients with type\u00a02 diabetes. N\u00a0Engl J Med. 2016;375:1834\u201344.","journal-title":"N Engl J Med"},{"key":"2671_CR95","doi-asserted-by":"publisher","first-page":"430","DOI":"10.2337\/dc24-1773","volume":"48","author":"EM Apperloo","year":"2025","unstructured":"Apperloo\u00a0EM, et\u00a0al. Tirzepatide associated with reduced Albuminuria in participants with type\u00a02 diabetes: pooled post hoc analysis from the randomized active- and placebo-controlled SURPASS-1\u20135 clinical trials. Diabetes Care. 2025;48:430\u20136.","journal-title":"Diabetes Care"},{"key":"2671_CR96","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1007\/s00108-012-3203-6","volume":"53","author":"G Schernthaner","year":"2012","unstructured":"Schernthaner\u00a0G, Schernthaner\u00a0GH. Current treatment of type\u00a02 diabetes. Internist. 2012;53:1399\u2013410.","journal-title":"Internist"},{"key":"2671_CR97","doi-asserted-by":"publisher","first-page":"948","DOI":"10.3390\/jcm4050948","volume":"4","author":"M Alsahli","year":"2015","unstructured":"Alsahli\u00a0M, Gerich\u00a0JE. Hypoglycemia in patients with diabetes and renal disease. J\u00a0Clin Med. 2015;4:948\u201364.","journal-title":"J Clin Med"},{"key":"2671_CR98","doi-asserted-by":"publisher","first-page":"359","DOI":"10.2165\/00003088-199630050-00003","volume":"30","author":"AJ Scheen","year":"1996","unstructured":"Scheen\u00a0AJ. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 1996;30:359\u201371.","journal-title":"Clin Pharmacokinet"},{"key":"2671_CR99","doi-asserted-by":"publisher","first-page":"c380","DOI":"10.1159\/000323739","volume":"118","author":"HJ Nye","year":"2011","unstructured":"Nye\u00a0HJ, Herrington\u00a0WG. Metformin: the safest hypoglycaemic agent in chronic kidney disease? Nephron Clin Pract. 2011;118:c380\u2013c3.","journal-title":"Nephron Clin Pract"},{"key":"2671_CR100","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/j.1440-1797.2010.01328.x","volume":"15","author":"HL Pilmore","year":"2010","unstructured":"Pilmore\u00a0HL. Review: metformin: potential benefits and use in chronic kidney disease. Nephrology. 2010;15:412\u20138.","journal-title":"Nephrology"},{"key":"2671_CR101","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.1001\/jama.2014.15298","volume":"312","author":"SE Inzucchi","year":"2014","unstructured":"Inzucchi\u00a0SE, Lipska\u00a0KJ, Mayo\u00a0H, Bailey\u00a0CJ, McGuire\u00a0DK. Metformin in patients with type\u00a02 diabetes and kidney disease: a\u00a0systematic review. JAMA. 2014;312:2668\u201375.","journal-title":"JAMA"},{"key":"2671_CR102","doi-asserted-by":"publisher","first-page":"547","DOI":"10.2337\/dc17-2231","volume":"41","author":"JD Lalau","year":"2018","unstructured":"Lalau\u00a0JD, et\u00a0al. Metformin treatment in patients with type\u00a02 diabetes and chronic kidney disease stages 3A, 3B, or 4. Diabetes Care. 2018;41:547\u201353.","journal-title":"Diabetes Care"},{"issue":"Suppl 2","key":"2671_CR103","doi-asserted-by":"publisher","first-page":"ii1","DOI":"10.1093\/ndt\/gfv100","volume":"30","author":"Guideline development, g.","year":"2015","unstructured":"Guideline development, g.. Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage\u00a03b or higher (eGFR \u3008\u202f45\u202fmL\/min). Nephrol Dial Transplant. 2015;30(Suppl 2):ii1\u2013142.","journal-title":"Nephrol Dial Transplant"},{"key":"2671_CR104","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.diabres.2015.07.002","volume":"110","author":"SP Chan","year":"2015","unstructured":"Chan\u00a0SP, Colagiuri\u00a0S. Systematic review and meta-analysis of the efficacy and hypoglycemic safety of gliclazide versus other insulinotropic agents. Diabetes Res Clin Pract. 2015;110:75\u201381.","journal-title":"Diabetes Res Clin Pract"},{"key":"2671_CR105","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1111\/j.1463-1326.2008.00928.x","volume":"10","author":"J Tayek","year":"2008","unstructured":"Tayek\u00a0J. SUR receptor activity vs. incidence of hypoglycaemia and cardiovascular mortality with sulphonylurea therapy for diabetics. Diabetes Obes Metab. 2008;10:1128\u20139. author reply 1129\u20131130.","journal-title":"Diabetes Obes Metab"},{"key":"2671_CR106","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/j.1464-5491.2004.01426.x","volume":"22","author":"BH Charbonnel","year":"2005","unstructured":"Charbonnel\u00a0BH, et\u00a0al. A\u00a0long-term comparison of pioglitazone and gliclazide in patients with Type\u00a02 diabetes mellitus: a\u00a0randomized, double-blind, parallel-group comparison trial. Diabet Med. 2005;22:399\u2013405.","journal-title":"Diabet Med"},{"key":"2671_CR107","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2337\/diacare.27.1.141","volume":"27","author":"M Hanefeld","year":"2004","unstructured":"Hanefeld\u00a0M, et\u00a0al. One-year glycemic control with a\u00a0sulfonylurea plus pioglitazone versus a\u00a0sulfonylurea plus metformin in patients with type\u00a02 diabetes. Diabetes Care. 2004;27:141\u20137.","journal-title":"Diabetes Care"},{"key":"2671_CR108","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/dmrr.478","volume":"21","author":"DR Matthews","year":"2005","unstructured":"Matthews\u00a0DR, Charbonnel\u00a0BH, Hanefeld\u00a0M, Brunetti\u00a0P, Schernthaner\u00a0G. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type\u00a02 diabetes: a\u00a0randomized, comparative study. Diabetes Metab Res Rev. 2005;21:167\u201374.","journal-title":"Diabetes Metab Res Rev"},{"key":"2671_CR109","doi-asserted-by":"publisher","first-page":"6068","DOI":"10.1210\/jc.2003-030861","volume":"89","author":"G Schernthaner","year":"2004","unstructured":"Schernthaner\u00a0G, et\u00a0al. Efficacy and safety of pioglitazone versus metformin in patients with type\u00a02 diabetes mellitus: a\u00a0double-blind, randomized trial. J\u00a0Clin Endocrinol Metab. 2004;89:6068\u201376.","journal-title":"J Clin Endocrinol Metab"},{"key":"2671_CR110","doi-asserted-by":"publisher","first-page":"5931","DOI":"10.1111\/dom.15967","volume":"26","author":"L Vanek","year":"2024","unstructured":"Vanek\u00a0L, Kurnikowski\u00a0A, Krenn\u00a0S, Mussnig\u00a0S, Hecking\u00a0M. Semaglutide in patients with kidney failure and obesity undergoing dialysis and wishing to be transplanted: A\u00a0prospective, observational, open-label study. Diabetes Obes Metab. 2024;26:5931\u201341.","journal-title":"Diabetes Obes Metab"},{"key":"2671_CR111","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.2337\/dci17-0026","volume":"40","author":"IH de Boer","year":"2017","unstructured":"de Boer\u00a0IH, et\u00a0al. Diabetes and hypertension: a\u00a0position statement by the American Diabetes Association. Diabetes Care. 2017;40:1273\u201384.","journal-title":"Diabetes Care"},{"key":"2671_CR112","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00508-019-01565-0","volume":"131","author":"T Weber","year":"2019","unstructured":"Weber\u00a0T, et\u00a0al. Austrian Consensus on High Blood Pressure 2019. Wien Klin Wochenschr. 2019;131:489\u2013590.","journal-title":"Wien Klin Wochenschr"},{"key":"2671_CR113","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1053\/j.ajkd.2013.03.018","volume":"62","author":"SJ Taler","year":"2013","unstructured":"Taler\u00a0SJ, et\u00a0al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD. Am J Kidney Dis. 2013;62:201\u201313.","journal-title":"Am J Kidney Dis"},{"key":"2671_CR114","doi-asserted-by":"publisher","first-page":"884","DOI":"10.7326\/0003-4819-144-12-200606200-00005","volume":"144","author":"FH Messerli","year":"2006","unstructured":"Messerli\u00a0FH, et\u00a0al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med. 2006;144:884\u201393.","journal-title":"Ann Intern Med"},{"key":"2671_CR115","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1001\/archinternmed.2011.619","volume":"172","author":"CA Peralta","year":"2012","unstructured":"Peralta\u00a0CA, et\u00a0al. Blood pressure components and end-stage renal disease in persons with chronic kidney disease: the Kidney Early Evaluation Program (KEEP). Arch Intern Med. 2012;172:41\u20137.","journal-title":"Arch Intern Med"},{"key":"2671_CR116","doi-asserted-by":"publisher","first-page":"233","DOI":"10.7326\/0003-4819-159-4-201308200-00004","volume":"159","author":"CP Kovesdy","year":"2013","unstructured":"Kovesdy\u00a0CP, et\u00a0al. Blood pressure and mortality in U.S. veterans with chronic kidney disease: a\u00a0cohort study. Ann Intern Med. 2013;159:233\u201342.","journal-title":"Ann Intern Med"},{"key":"2671_CR117","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","volume":"329","author":"EJ Lewis","year":"1993","unstructured":"Lewis\u00a0EJ, Hunsicker\u00a0LG, Bain\u00a0RP, Rohde\u00a0RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N\u00a0Engl J Med. 1993;329:1456\u201362.","journal-title":"N Engl J Med"},{"key":"2671_CR118","doi-asserted-by":"publisher","first-page":"i438","DOI":"10.1136\/bmj.i438","volume":"352","author":"S Bangalore","year":"2016","unstructured":"Bangalore\u00a0S, Fakheri\u00a0R, Toklu\u00a0B, Messerli\u00a0FH. Diabetes mellitus as a\u00a0compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials. BMJ. 2016;352:i438.","journal-title":"BMJ"},{"key":"2671_CR119","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","volume":"369","author":"LF Fried","year":"2013","unstructured":"Fried\u00a0LF, et\u00a0al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N\u00a0Engl J Med. 2013;369:1892\u2013903.","journal-title":"N Engl J Med"},{"key":"2671_CR120","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","volume":"367","author":"HH Parving","year":"2012","unstructured":"Parving\u00a0HH, et\u00a0al. Cardiorenal end points in a\u00a0trial of aliskiren for type\u00a02 diabetes. N\u00a0Engl J Med. 2012;367:2204\u201313.","journal-title":"N Engl J Med"},{"key":"2671_CR121","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","volume":"372","author":"JF Mann","year":"2008","unstructured":"Mann\u00a0JF, et\u00a0al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a\u00a0multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372:547\u201353.","journal-title":"Lancet"},{"key":"2671_CR122","doi-asserted-by":"publisher","first-page":"498","DOI":"10.34067\/KID.0000000777","volume":"6","author":"R Liu","year":"2025","unstructured":"Liu\u00a0R, Lu\u00a0Y, Juncos\u00a0LA. From receptor to repair: the mechanistic basis of mineralocorticoid receptor antagonism in acute kidney injury and CKD. Kidney. 2025;6:498\u2013500.","journal-title":"Kidney"},{"key":"2671_CR123","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris\u00a0GL, et\u00a0al. Effect of finerenone on chronic kidney disease outcomes in type\u00a02 diabetes. N\u00a0Engl J Med. 2020;383:2219\u201329.","journal-title":"N Engl J Med"},{"key":"2671_CR124","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt\u00a0B, et\u00a0al. Cardiovascular events with finerenone in kidney disease and type\u00a02 diabetes. N\u00a0Engl J Med. 2021;385:2252\u201363.","journal-title":"N Engl J Med"},{"key":"2671_CR125","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","volume":"43","author":"R Agarwal","year":"2022","unstructured":"Agarwal\u00a0R, et\u00a0al. Cardiovascular and kidney outcomes with finerenone in patients with type\u00a02 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart\u00a0J. 2022;43:474\u201384.","journal-title":"Eur Heart J"},{"key":"2671_CR126","doi-asserted-by":"crossref","unstructured":"Agarwal R, et\u00a0al. Finerenone with empagliflozin in chronic kidney disease and type\u00a02 diabetes. N\u00a0Engl J Med. 2025;.","DOI":"10.2337\/db25-1863-LB"},{"key":"2671_CR127","doi-asserted-by":"publisher","first-page":"110908","DOI":"10.1016\/j.diabres.2023.110908","volume":"204","author":"HJL Heerspink","year":"2023","unstructured":"Heerspink\u00a0HJL, et\u00a0al. Rationale and design of a\u00a0randomised phase\u00a0III registration trial investigating finerenone in participants with type\u00a01 diabetes and chronic kidney disease: the FINE-ONE trial. Diabetes Res Clin Pract. 2023;204:110908.","journal-title":"Diabetes Res Clin Pract"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-025-02671-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-025-02671-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-025-02671-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T22:18:43Z","timestamp":1779315523000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00508-025-02671-y"}},"subtitle":["Leitlinie in Zusammenarbeit der \u00d6sterreichischen Diabetes Gesellschaft und der \u00d6sterreichischen Gesellschaft f\u00fcr Nephrologie","Guidelines in a\u00a0collaboration of the Austrian Diabetes Association and the Austrian Society of Nephrology"],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":127,"journal-issue":{"issue":"S4","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["2671"],"URL":"https:\/\/doi.org\/10.1007\/s00508-025-02671-y","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"assertion":[{"value":"10 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.\u00a0Sourij hat von folgenden Unternehmen Honorare f\u00fcr Vortr\u00e4ge oder Beratert\u00e4tigkeit erhalten: Amarin, Amgen, AstraZeneca, Boehringer Ingelheim, Bayer, Daiichi Sankyo, Eli Lilly, Novo Nordisk, Novartis, Sanofi-Aventis, Sobi. F.\u00a0Aberer hat von folgenden Unternehmen Reiseunterst\u00fctzung, Honorare f\u00fcr Vortr\u00e4ge, Beratert\u00e4tigkeit oder Forschungsunterst\u00fctzungen erhalten: Amgen, Bayer, Sanofi, Novo Nordisk, AstraZeneca und Boehringer Ingelheim. M.\u00a0Antlanger hat von folgenden Unternehmen Honorare f\u00fcr Vortr\u00e4ge oder Beratert\u00e4tigkeit erhalten: Boehringer Ingelheim, Bayer, CSL Vifor. J.\u00a0Brix hat von folgenden Unternehmen Honorare f\u00fcr Vortr\u00e4ge, Beratert\u00e4tigkeit sowie Forschungsunterst\u00fctzung erhalten: Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Dexcom, Eli Lilly, Medtronic, Novo Nordisk. D.\u00a0Cejka hat von folgenden Unternehmen Honorare f\u00fcr Vortr\u00e4ge erhalten: AstraZeneca, Boehringer Ingelheim und Bayer. M.\u00a0Clodi hat von folgenden Unternehmen Honorare f\u00fcr Vortr\u00e4ge und Beratert\u00e4tigkeit erhalten: Novo Nordisk, Elli Lilly, Boehringer Ingelheim, AstraZeneca, Novartis, Daiichi Sankyo, Amgen, W\u00f6rwag, Sanofi, Amarin, Roche, Bayer, Sobi. R.\u00a0Edlinger hat von folgenden Unternehmen Kongressunterst\u00fctzung, Honorar f\u00fcr Vortr\u00e4ge oder Beratert\u00e4tigkeit erhalten: Amgen, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Fresenius Kabi, Medice, Novartis, Sanofi-Aventis, Stada, Vifor. K.\u00a0Eller: Beratungs- und Referentenhonorare: CSL Vifor, B\u00f6hringer Ingelheim, AstraZeneca, Novo Nordisk, Lilly, Novartis, Alexion, Sanofi, GSK, Chiesi, Otsuka. S.\u00a0Horn hat von folgenden Unternehmen Honorare f\u00fcr Vortr\u00e4ge oder Beratert\u00e4tigkeit erhalten: Boehringer Ingelheim, Bayer, CSL Vifor, Otsula, Eli Lilly, Fresenius, AstraZeneca, Sanofi\u00a0\u2013 Aventis, Novo Nordisk. S.\u00a0Kaser hat Vortragshonorare bzw. Beraterhonorare erhalten von Novo Nordisk, Eli Lilly, Sanofi. A.\u00a0Kautzky-Willer hat von folgenden Unternehmen, die auch tlw. f\u00f6rdernde Mitglieder der \u00d6DG sind, Forschungsunterst\u00fctzungen und\/oder Honorare erhalten: Bayer, Boehringer Ingelheim, Amgen, Novartis, Novo Nordisk, Lilly. M.\u00a0Leutner hat von folgenden Unternehmen, die auch tlw. f\u00f6rdernde Mitglieder der \u00d6DG sind, Forschungsunterst\u00fctzungen und\/oder Honorare erhalten: Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Novartis, Novo Nordisk. R.\u00a0Oberbauer hat Vortragshonorare bzw. Beraterhonorare von Neovii, Sanofi, Vifor, Diasorin erhalten. M.\u00a0Pirklbauer hat von folgenden Unternehmen Reisekostenunterst\u00fctzung, Honorare f\u00fcr Vortr\u00e4ge oder Beratert\u00e4tigkeit erhalten: AstraZeneca, Boehringer Ingelheim. D.\u00a0Strobl hat von folgenden Unternehmen Kongressunterst\u00fctzung, Honorar f\u00fcr Vortr\u00e4ge oder Beratert\u00e4tigkeit erhalten: Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Novartis, Novo Nordisk. M.\u00a0S\u00e4emann hat Beratungs- und Sprecherhonorare erhalten von Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, CSL Vifor, Eli Lilly, GSK, Novartis, Novo Nordisk, Otsuka. A.R.\u00a0Rosenkranz, S.\u00a0Schmaldienst und H.\u00a0Stingl geben an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Offenlegungen"}}]}}